Seres Therapeutics (MCRB) EPS (Weighted Average and Diluted) (2020 - 2025)
Seres Therapeutics (MCRB) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$1.76 as the latest value for Q4 2025.
- Quarterly EPS (Weighted Average and Diluted) fell 111.99% to -$1.76 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.66 through Dec 2025, down 96.0% year-over-year, with the annual reading at $0.64 for FY2025, 96.05% down from the prior year.
- EPS (Weighted Average and Diluted) hit -$1.76 in Q4 2025 for Seres Therapeutics, down from $0.94 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $14.68 in Q4 2024 to a low of -$16.55 in Q4 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.14 across 5 years, with a median of -$0.54 in 2022.
- Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 2964.81% in 2023 and later skyrocketed 3734.38% in 2024.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.55 in 2021, then grew by 1.82% to -$0.54 in 2022, then crashed by 2964.81% to -$16.55 in 2023, then soared by 188.7% to $14.68 in 2024, then tumbled by 111.99% to -$1.76 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for MCRB at -$1.76 in Q4 2025, $0.94 in Q3 2025, and -$2.27 in Q2 2025.